Markets:

Overview

News

Currencies

International

Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

59.45 +0.02 (+0.03%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

What To Expect From United Therapeutics’s (UTHR) Q4 Earnings

February 25, 2025

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know.

Via StockStory

What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings

February 23, 2025

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know.

Via StockStory

Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today ↗

February 20, 2025

Via The Motley Fool

Demystifying Biomarin Pharmaceutical: Insights From 8 Analyst Reviews ↗

February 20, 2025

Via Benzinga

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today

February 20, 2025

Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company reported impressive fourth-quarter results, exceeding analysts' sales and EPS...

Via StockStory

Earnings Scheduled For February 19, 2025 ↗

February 19, 2025

Via Benzinga

NASDAQ:BMRN, a growth stock which is not overvalued. ↗

December 24, 2024

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.

Via Chartmill

Why Is BioMarin Stock Trading Higher On Thursday? ↗

February 20, 2025

BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.

Via Benzinga

BioMarin: EPS Surges Past Expectations ↗

February 19, 2025

BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results.

Via The Motley Fool

BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars

February 19, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 15.6% year on year to $747.3 million. The company’s full-year...

Via StockStory

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings

February 18, 2025

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know.

Via StockStory

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? ↗

February 13, 2025

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.

Via Benzinga

The Latest Analyst Ratings For Biomarin Pharmaceutical ↗

December 12, 2024

Via Benzinga

The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical ↗

November 15, 2024

Via Benzinga

Peering Into Biomarin Pharmaceutical's Recent Short Interest ↗

November 06, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 12, 2025

Via Benzinga

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. ↗

February 04, 2025

NASDAQ:BMRN is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.

Via Chartmill

NASDAQ:BMRN is an undervalued gem with solid fundamentals. ↗

January 27, 2025

Take a closer look at BIOMARIN PHARMACEUTICAL INC , a remarkable value stock. NASDAQ:BMRN excels in fundamentals and maintains a very reasonable valuation.

Via Chartmill

Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? ↗

January 19, 2025

Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX,...

Via Benzinga

NASDAQ:BMRN is showing decent growth, but is still valued reasonably. ↗

January 14, 2025

Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical ↗

October 30, 2024

Via Benzinga

Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators ↗

January 08, 2025

Alger launched its INVN ETF, with holdings including BioMarin, Teradata, and Bristol-Myers Squibb.

Via Benzinga

Topics ETFs

10 Magnificent Stocks That Can Make You Richer in 2025 ↗

January 03, 2025

A new year brings with it new opportunities to grow your wealth on Wall Street.

Via The Motley Fool

NASDAQ:BMRN stands out as a stock that provides good value for the fundamentals it showcases. ↗

December 27, 2024

In a market where value is scarce, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering. ↗

December 02, 2024

Despite its growth, NASDAQ:BMRN remains within the realm of affordability.

Via Chartmill

When you look at NASDAQ:BMRN, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

November 22, 2024

In a market where value is scarce, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

Can BioMarin Stock Live Up to Wall Street’s High Expectations?

November 22, 2024

BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?

Via MarketBeat

NASDAQ:BMRN stands out as a growth opportunity that won't break the bank. ↗

November 11, 2024

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) is showing decent growth, but is still valued reasonably.

Via Chartmill

CAMP4 Analyst Highlights Rare Disease Platform Potential ↗

November 05, 2024

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts project $1 billion in revenue for UCD drug by 2036.

Via Benzinga

Topics Initial Public Offering

BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth ↗

October 30, 2024

BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.